Adaptimmune Therapeutics Plc Asset Resilience Ratio

Latest as of June 2025: 0.00%

Adaptimmune Therapeutics Plc asset resilience ratio. Adaptimmune Therapeutics Plc (ADAP) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Adaptimmune Therapeutics Plc (ADAP) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$0.00

Cash + Short-term Investments

Total Assets

$130.63 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Adaptimmune Therapeutics Plc (2013–2024)

Asset resilience ratio of Adaptimmune Therapeutics Plc from 2013 to 2024. This chart shows how Adaptimmune Therapeutics Plc's Asset Resilience Ratio has changed over time. Read total liabilities of Adaptimmune Therapeutics Plc for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Adaptimmune Therapeutics Plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Adaptimmune Therapeutics Plc assets under control.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$0.00	0%
Total Liquid Assets	$0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Adaptimmune Therapeutics Plc maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Adaptimmune Therapeutics Plc Industry Peers by Asset Resilience Ratio

Compare Adaptimmune Therapeutics Plc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Adaptimmune Therapeutics Plc Asset Resilience Ratio by Year (2013–2024)

Adaptimmune Therapeutics Plc asset resilience ratio by year from 2013 to 2024. The table below shows the annual Asset Resilience Ratio data for Adaptimmune Therapeutics Plc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	24.58%	$60.47 Million	$245.96 Million	+23.54pp
2023-12-31	1.04%	$2.95 Million	$282.62 Million	-28.32pp
2022-12-31	29.36%	$96.57 Million	$328.92 Million	-17.41pp
2021-12-31	46.78%	$219.63 Million	$469.55 Million	-22.23pp
2020-12-31	69.01%	$311.33 Million	$451.14 Million	+47.46pp
2019-12-31	21.55%	$39.13 Million	$181.54 Million	-27.86pp
2018-12-31	49.42%	$136.75 Million	$276.74 Million	+5.23pp
2017-12-31	44.18%	$124.22 Million	$281.15 Million	+34.51pp
2016-12-31	9.68%	$22.69 Million	$234.51 Million	-8.71pp
2015-12-31	18.39%	$55.30 Million	$300.68 Million	0.00pp
2014-12-31	18.39%	$55.30 Million	$300.68 Million	-80.68pp
2013-12-31	99.07%	$55.00 Million	$55.52 Million	--

pp = percentage points

About Adaptimmune Therapeutics Plc

NASDAQ:ADAP USA Biotechnology

Market Cap

$9.54 Million

Market Cap Rank

#27041 Global

#5619 in USA

Share Price

$0.04

Change (1 day)

+0.00%

52-Week Range

$0.04 - $0.04

All Time High

$14.16